The purpose of this phase III study is to determine the safety and efficacy of difluprednate
in the management of inflammation following ocular surgery.
- Scheduled for unilateral ocular surgery.
- Systemic administration of any corticosteroid or immunosuppressive drug in the 2
weeks prior to study enrollment.